← All trials
NCT06638931
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2024
- Primary completion
- Jul 31, 2026
- Completion date
- May 31, 2028
- First posted
- Oct 15, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 28
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Instituto do Cancer do Estado de São PauloLead sponsor
- Instituto do Cancer do Estado de São PauloSponsor investigator
Drugs studied
Indications studied
- Carcinoma, Ovarian Epithelial
- Adrenal Gland Neoplasms
- Anus Neoplasms
- Biliary Tract Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Renal Cell
- Carcinosarcoma
- Carcinoma, Adenoid Cystic
- Fallopian Tube Neoplasms
- Fibrosarcoma
- Gallbladder Neoplasms
- Granulosa Cell Tumor
- Hemangiosarcoma
- Intestinal Neoplasms
- Leiomyosarcoma
- Liver Neoplasms
- Mesothelioma
- Neoplasms
- Neuroblastoma
- Parathyroid Neoplasms
- Penile Neoplasms
- Sarcoma
- Sarcoma, Kaposi
- Osteosarcoma
- Thyroid Neoplasms
- Trophoblastic Neoplasms
- Urethral Neoplasms
- Vaginal Neoplasms
- Vulvar Neoplasms
- Endometrial Neoplasms
- Hepatoblastoma
- Endodermal Sinus Tumor
- Neuroectodermal Tumors, Primitive
- Cholangiocarcinoma
- Sertoli-Leydig Cell Tumor
- Neurofibrosarcoma
- Hemangioblastoma
- Neuroendocrine Tumors
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.